
    
      Phase 1 Dose Escalation: To evaluate the overall safety profile, efficacy of TPX-0131 in
      pretreated subjects with ALK+ advanced or metastatic NSCLC.

      Phase 2 Efficacy Evaluation: To determine the safety and anti-tumor efficacy of TPX-0131 in
      defined cohorts of subjects with advanced or metastatic ALK+ NSCLC.
    
  